title: Reconsidering Current Decorporation Strategies after Incorporation of Radionuclides.
abstract: In the case of a nuclear accident or a terrorist attack by a "dirty bomb," there is a risk of external and internal contamination with radionuclides in addition to external irradiation. Internal irradiation as a consequence of radionuclide incorporation is associated with a higher risk of stochastic radiation effects (e.g., tumors). Decorporation treatment will enhance the elimination of radionuclides and reduce the committed effective dose as a metric of stochastic health effects. Although treatment efficacy is better when started early, beginning the therapy without knowing the committed effective dose may unnecessarily expose the patient to the side effects of the medication. The question is: Delay the therapy to wait for the results of internal dosimetry or start the therapy promptly on spec? To prove insight into this question, a selective review of the literature was conducted. The importance of the initiation time of treatment in the efficacy of decorporation treatment can be explained with pharmacokinetic laws and first order processes determining the disposition of xenobiotics in the organism. Nevertheless, there is no internationally accepted standard on when to start a decorporation therapy (exception: iodide). The "precautionary approach," emphasizing the importance of the committed effective dose for the indication of treatment, is competing with the "urgent approach" advocating the administration of medication "a priori" within several hours. A review of the literature actually indicates that the most important drugs used for decorporation are well tolerated with few adverse effects. In consideration of the higher efficacy and the low side-effects of a short-term treatment, initiating decorporation therapy as soon as possible after internal contamination, even before the committed effective dose has been assessed, appears to be a reasonable approach. The decision of continuation or discontinuation of the therapy should be taken after internal dosimetry is completed on the basis of the committed effective dose.
authors.affiliation: *Institute of Radiobiology of the Bundeswehr, Munich; †Applied Research Associates Inc., Arlington.
authors.forename: A
authors.initials: A
authors.lastname: Rump
authors.forename: D
authors.initials: D
authors.lastname: Stricklin
authors.forename: A
authors.initials: A
authors.lastname: Lamkowski
authors.forename: S
authors.initials: S
authors.lastname: Eder
authors.forename: M
authors.initials: M
authors.lastname: Abend
authors.forename: M
authors.initials: M
authors.lastname: Port
mesh_terms: D000818:Animals; D002614:Chelating Agents / Q000008:administration & dosage*; D003666:Decontamination / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D011868:Radioisotopes / Q000302:isolation & purification* / Q000506:poisoning; D055502:Secondary Prevention / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D002614:Chelating Agents; D011837:Radiation-Protective Agents; D011868:Radioisotopes